Evidence map›Paper›PMID 26409478›Full record

ReviewMolecular neurobiology2016

Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease.

Bharath Wootla, Aleksandar Denic, Jens O Watzlawik, Arthur E Warrington, Moses Rodriguez

Open access · hybridAbstract readReview
In one paragraph

Review in Molecular neurobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Relapse recovery: The forgotten variable in multiple sclerosis clinical trials.Neurology(R) neuroimmunology & neuroinflammation · 2020
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bharath WootlaDepartments of Neurology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Aleksandar DenicDepartments of Neurology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Jens O WatzlawikDepartments of Neurology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Arthur E WarringtonDepartments of Neurology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Moses RodriguezDepartments of Neurology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA. Rodriguez.Moses@mayo.edu.ORCID 0000-0001-6328-6497
Mayo Clinic · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Nanopore Biosensor for Kinetics of Reparative Antibodies on Plasma MembranesR01GM092993 · NIGMS · UNIVERSITY OF MINNESOTA · PI OH, SANG-HYUN · 2010 to 2013
$1.6M
Genetic Analysis of Spontaneous RemyelinationR01NS048357 · NINDS · MAYO CLINIC ROCHESTER · PI BIEBER, ALLAN JAMES · 2008 to 2011
$1.0M
Clinical Translation of a Neuron Protective Recombinant Human AntibodyR21NS073684 · NINDS · MAYO CLINIC ROCHESTER · PI RODRIGUEZ, MOSES · 2011 to 2012
$434k
NCATS NIH HHS UL1 TR000135NIGMS NIH HHS R01 GM092993NINDS NIH HHS R01 NS048357NINDS NIH HHS R21 NS073684
6 · The paper itself

Abstract

Demyelination underlies early neurological symptoms in multiple sclerosis (MS); however, axonal damage is considered critical for permanent chronic deficits. The precise mechanisms by which axonal injury occurs in MS are unclear; one hypothesis is the absence or failure of remyelination, suggesting that promoting remyelination may protect axons from death. This report provides direct evidence that promoting oligodendrocyte remyelination protects axons and maintains transport function. Persistent Theiler's virus infection of Swiss Jim Lambert (SJL)/J mice was used as a model of MS to assess the effects of remyelination on axonal injury following demyelination in the spinal cord. Remyelination was induced using an oligodendrocyte/myelin-specific recombinant human monoclonal IgM, rHIgM22. The antibody is endowed with strong anti-apoptotic and pro-proliferative effects on oligodendrocyte progenitor cells. We used (1)H-magnetic resonance spectroscopy (MRS) at the brainstem to measure N-acetyl-aspartate (NAA) as a surrogate of neuronal health and spinal cord integrity. We found increased brainstem NAA concentrations at 5 weeks post-treatment with rHIgM22, which remained stable out to 10 weeks. Detailed spinal cord morphology studies revealed enhanced remyelination in the rHIgM22-treated group but not in the isotype control antibody- or saline-treated groups. Importantly, we found rHIgM22-mediated remyelination protected small- and medium-caliber mid-thoracic spinal cord axons from damage despite similar demyelination and inflammation across all experimental groups. The most direct confirmation of remyelination-mediated protection of descending neurons was an improvement in retrograde transport. Treatment with rHIgM22 significantly increased the number of retrograde-labeled neurons in the brainstem, indicating that preserved axons are functionally competent. This is direct validation that remyelination preserves spinal cord axons and protects functional axon integrity.

Indexed as

AnimalsAntibodiesAspartic AcidAxonsBrain StemCardiovirus InfectionsDemyelinating DiseasesMiceOligodendrogliaRemyelinationSpinal CordTheilovirusAntibodiesAspartic AcidN-acetylaspartateAntibodyAxonsBrainstemMagnetic resonance spectroscopyMultiple sclerosisN-acetyl-aspartateProtectionRemyelinationTheiler’s murine encephalomyelitis virus

Identifiers

PMID26409478
PMCPMC5012151
OpenAlexW2122464368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.